Company profile: ViaCord
1.1 - Company Overview
Company description
- Provider of women's health biotechnology services, including ViaCord for preserving newborn umbilical cord blood, cord tissue banking, and ViaCyte for cryopreservation of unfertilized eggs, plus newborn genomic offerings such as DNA preservation, celiac and lactose risk testing, a panel analyzing over 270 genes, and whole genome sequencing of 22,000 genes.
Products and services
- Cord Blood Banking: Stem-cell–based service that collects and stores a newborn’s umbilical cord blood for possible future medical use, preserving blood containing stem cells applicable to medical treatments
- Cord Tissue Banking: Multi-stem-cell–type service that collects and stores tissue from a newborn’s umbilical cord, preserving different stem cell types that can be used for medical treatments
- Whole Genome Sequencing: Genome-wide service that sequences all 22,000 genes in a newborn’s DNA to identify variants associated with childhood onset conditions and drug sensitivities
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to ViaCord
Sprint Bioscience
HQ: Sweden
Website
- Description: Provider of a fragment-based, modular gene-to-lead drug discovery platform covering protein expression/purification, fragment screening, X-ray crystallography, and fragment-to-lead expansion. Develops small-molecule candidates from idea to preclinical stage for licensing. Programs: TREX1 (DISA), VRK1 (VADA, licensed to Day One Biopharmaceuticals), NNMT (NIMA). Based in Stockholm, Sweden.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sprint Bioscience company profile →
Ziylo
HQ: United Kingdom
Website
- Description: Provider of biomimetic glucose binding molecules (GBM) based on supramolecular chemistry for use in diabetes care, enabling Continuous Glucose Monitors (CGM) and Glucose Responsive Insulins (GRI), with a mission to help people with diabetes live more normal and longer lives.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ziylo company profile →
Algenex
HQ: Spain
Website
- Description: Provider of vector-based technologies to manufacture recombinant proteins via a baculovirus expression vector system, with applications in vaccines, diagnostic reagents, crystallography, HTS and therapeutic molecules. Offers CrisBio, animal vaccine development/production, and biocomponents for diagnostic and therapeutic markets in human and animal health.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Algenex company profile →
BioLegend
HQ: United States
Website
- Description: Provider of immunological reagents for biomedical research, developing antibodies, recombinant proteins, bioassays, and other research reagents at a state-of-the-art facility in San Diego, California.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioLegend company profile →
Primity Bio
HQ: United States
Website
- Description: Provider of biomarker and immune monitoring services, offering innovative flow cytometry platforms to biopharma for use throughout the drug discovery process, from lead selection to clinical trial sample analysis, with specialized discovery platforms for profiling cell surface and intracellular signaling proteins.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Primity Bio company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for ViaCord
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to ViaCord
2.2 - Growth funds investing in similar companies to ViaCord
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for ViaCord
4.2 - Public trading comparable groups for ViaCord
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →